Here we show that Doxil® has minimal antitumour activity in the isolated limb perfusion (ILP) setting and its activity was not enhanced by the addition of tumour necrosis factor (TNF). Doxil® accumulation in tumour tissue was low and also not augmented by TNF. In contrast, activity of free conventional doxorubicin was enhanced by TNF. We conclude that application of Doxil® in a TNF-based ILP is not a useful alternative to free conventional doxorubicin or melphalan. © 2004 Cancer Research UK.
CITATION STYLE
Ten Hagen, T. L. M., Hoving, S., Ambagtsheer, G., Van Tiel, S. T., & Eggermont, A. M. M. (2004). Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats. British Journal of Cancer, 90(9), 1830–1832. https://doi.org/10.1038/sj.bjc.6601688
Mendeley helps you to discover research relevant for your work.